Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
Listen
(2 min)
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
Listen
(2 min)
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
https://www.wsj.com/articles/roivant-in-talks-to-sell-stomach-drug-to-roche-in-deal-valued-at-more-than-7-billion-c68e3f3f
WSJ News Exclusive
By
,
and
Updated July 13, 2023 6:41 pm ET
Listen
(2 min)
Roivant Sciences, a biotech company started by Republican presidential candidate Vivek Ramaswamy, is in talks to sell an experimental drug for a debilitating stomach disease to Roche Holding, in a deal that could be valued at more than $7 billion.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Continue reading your article with
a WSJ subscription
Already a subscriber?
Sign In
WSJ Membership
Customer Service
Tools & Features
Ads
More
Dow Jones Products
WSJ Membership
Customer Service
Tools & Features
Ads
More
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
